
Virginia Cancer Institute Earns Prestigious QOPI® Certification - March, 2012
Virginia Cancer Institute Chosen for Patient Education Effort – March, 2012
At Virginia Cancer Institute, we provide treatment, support, and
follow-up care for people with cancer and blood disorders. Our purpose
is to provide our patients with care that includes efficiency and
compassion. The Virginia Cancer Institute is committed to offering care
in an atmosphere of professionalism, encouragement, and understanding.
Virginia Cancer Institute serves you by offering the best treatment
plans, answering questions to your satisfaction, and respecting your
informed decisions.
Virginia Cancer Institute's mission is to deliver high-quality,
comprehensive medical care while maintaining our patients' quality of
life. We offer a team approach for your cancer treatment by involving
experts in medical oncology, hematology, chemotherapy, and clinical
research.
The goal of our Web site is to:
We strive to promote respect, understanding, honesty, compassion,
integrity, teamwork, individuality, and confidentiality at all times. We
will remain committed to our purpose by remaining innovative and
continuously increasing our awareness of technological advancements and
the latest treatment methods. The physicians and staff continue to
strive to remain dedicated to this mission.
Virginia Cancer Institute is dedicated to understanding the causes,
prevention, and detection of cancer and blood disorders and to improving
the quality of life for individuals living with these conditionscancer.
Virginia Cancer Institute strives to be in the forefront of modern
cancer care through the thoughtful introduction of promising new methods
of treatment, the active participation in clinical research, the
recruitment, development and education of highly trained oncology
personnel, and the use of state-of-the art medical equipment.

Maintenance therapy with Revlimid® (lenalidomide) has been shown to significantly improve progression-free survival and time to progression in multiple myeloma, according to the results of three studies published in the New England Journal of Medicine. Multiple... Continue Reading
Maintenance therapy with Revlimid® (lenalidomide) has been shown to significantly improve progression-free survival and time to progression in multiple myeloma, according to the results of three studies published in the New England Journal of Medicine. Multiple... Continue Reading
Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet... Continue Reading